Τετάρτη, 6 Μαΐου 2020

Μήπως δεν εκτίθεστε όσο πρέπει;


Εκτεθείτε…. στον Ήλιο,

                                  Πάρτε συμπληρώματα Βιταμίνης D & 
                                                                                    Μειώστε τον κίνδυνο του καρκίνου!!

                                 Ο  Ήλιος, τα Συμπληρώματα και ο ρόλος της Βιταμίνης D 
                                 στη μείωση του κινδύνου και της εξέλιξης του καρκίνου!!!


Επιλογή, Επεξεργασία και Μετάφραση ερευνών:   Κατερίνα Μηστριώτη  -  Σύμβουλος Κλινικής Διατροφολογίας και Ολιστικών Εφαρμογών

Πηγές/Έρευνες /Ερευνητές:   Βλ. τέλος άρθρου



Σύμφωνα με σοβαρές επιστημονικές έρευνες, «οι γυναίκες με χαμηλά επίπεδα Βιταμίνης D στο αίμα, έχουν σχεδόν διπλάσιες (97%)  πιθανότητες να αναπτύξουν καρκίνο του μαστού σε σύγκριση με εκείνες με τα υψηλότερα επίπεδα».



Αποφεύγουμε τα χαμηλά επίπεδα απολαμβάνοντας καθημερινά, με σωστό τρόπο*, τον Ήλιο – χωρίς αντηλιακό και χωρίς γυαλιά ηλίου - και παίρνοντας συμπληρώματα διατροφής Βιταμίνης D.









Αυτός είναι ένας εύκολος, οικονομικός και ασφαλής τρόπος για τη μείωση:




α) της συχνότητας εμφάνισης,

β) την βελτίωση της πρόγνωσης και

γ) της έκβασης του καρκίνου!

(επιπλέον έρευνες βρίσκονται σε εξέλιξη)





Η Βιταμίνη D στην πραγματικότητα δεν είναι Βιταμίνη!

Είναι ο πρόδρομος της ισχυρής στεροειδούς ορμόνης καλσιτριόλης, η οποία έχει εκτεταμένες δράσεις σε ολόκληρο τον οργανισμό, ρυθμίζοντας  πολλές κυτταρικές διεργασίες που θα μπορούσαν να παίζουν ρόλο στην πρόληψη μιας σειράς καρκίνων (μαστού, παχέως εντέρου, ουροδόχου κύστεως, προστάτη αλλά και άλλων σοβαρών παθήσεων).  


Από την τροφή μας μπορούμε να πάρουμε ελάχιστη ποσότητα Βιταμίνης D (D3) από την συνολική που χρειαζόμαστε.
  

 Έτσι τα Συμπληρώματα και η  σωστή* έκθεσή μας στον Ήλιο,  είναι η   απάντηση!!!!  
            

 Σημείωση:  Η Bιταμίνη D3 εμπλέκεται σε έναν λεπτό χορό με   την Bιταμίνη  K2, και θα πρέπει να έχετε και τα δύο συστατικά σε συνεργικές   μεταξύ τους  και επαρκείς ποσότητες για να εξασφαλίσετε βέλτιστη υγεία. 

 Τα περισσότερα συμπληρώματα αποδίδουν αυτόν τον συνδυασμό.  




*Σωστός τρόπος έκθεσης στον ήλιο:

Καλοκαίρι:

Πρωί : μέχρι τις 12.00     Απόγευμα: από τις 18.00 και μετά

Τον υπόλοιπο χρόνο, ελεύθερα οποιαδήποτε ώρα και για τουλάχιστον συνολικά 45 λεπτά την ημέρα.





Πάντοτε ενυδατωμένοι το καλοκαίρι κατά την διάρκεια της έκθεσής μας στον ήλιο 
(πίνουμε συχνά νερό)











Εάν έχουμε ευαίσθητο δέρμα, είναι καλό να φοράμε ένα λεπτό λευκό μπλουζάκι που θα απομακρύνει την πιθανότητα εγκαύματος.




Φοράμε πάντοτε καπέλο ανοιχτόχρωμο με γείσο.


Αποφεύγουμε – όσο αυτό δεν μας ενοχλεί - τα γυαλιά ηλίου επειδή δίνουν στον εγκέφαλο  σήμα ότι επικρατεί συννεφιά και όχι ηλιοφάνεια. 




Ως αποτέλεσμα, ο εγκέφαλος δεν δίνει σήμα για παραγωγή μελανίνης… και η επιδερμίδα μας υποφέρει!



Όταν παράγεται μελανίνη, το δέρμα μας αποκτά ένα όμορφο φυσικό  μαύρισμα και δεν υπάρχει κανένας λόγος να χρησιμοποιήσουμε αντηλιακό το οποίο εμποδίζει την παραγωγή και εκμετάλλευση από τον οργανισμό της Βιταμίνης D

Το ίδιο ακριβώς κάνουν και τα μαύρα ενδύματα. 

Αποφεύγουμε τα μαύρα στην διάρκεια της ημέρας και για ενεργειακούς λόγους!


Είναι επίσης καλό στην διάρκεια του καλοκαιριού και της έκθεσής μας στον ήλιο, να ενισχύουμε τον οργανισμό μας με χλωροφύλλη.
    


 Μόλις 20 λεπτά  ηλιοφάνειας 
 (και έκθεσης στον ήλιο) 
 την ημέρα, 
 ενεργοποιεί το 
 σώμα σας ώστε να 
 απελευθερώσει 
 περισσότερα από


  200 αντιμικροβιακά 

  που καταπολεμούν: 

  τους μύκητες, 

  τα παράσιτα και 

  τους ιούς!!!!!

Εκτεθείτε ( στον ήλιο ) !!!!
      


 Έρευνες/Πηγές

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. 10.3322/caac.21492 [PubMed] [CrossRef[Google Scholar]
2. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med. 2002; 162:1985–93. 10.1001/archinte.162.17.1985 [PubMed] [CrossRef[Google Scholar]
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69:7–34. 10.3322/caac.21551 [PubMed] [CrossRef[Google Scholar]
4. Okazaki R. [Vitamin D and cancer]. Clin Calcium. 2014; 24:1193–99. [PubMed[Google Scholar]
5. Dunn JA, Jefferson K, MacDonald D, Iqbal G, Bland R. Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanism. J Steroid Biochem Mol Biol. 2019; 188:134–40. 10.1016/j.jsbmb.2019.01.002 [PubMed] [CrossRef[Google Scholar]
6. Li F, Zhao H, Hou L, Ling F, Zhang Y, Tan W. A higher circulating concentration of 25-hydroxyvitamin-D decreases the risk of renal cell carcinoma: a case-control study. Int Braz J Urol. 2019; 45:523–30. 10.1590/s1677-5538.ibju.2018.0186 [PMC free article] [PubMed] [CrossRef[Google Scholar]
7. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control. 2005; 16:83–95. 10.1007/s10552-004-1661-4 [PubMed] [CrossRef[Google Scholar]
8. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14:342–57. 10.1038/nrc3691 [PubMed] [CrossRef[Google Scholar]
9. Vanoirbeek E, Krishnan A, Eelen G, Verlinden L, Bouillon R, Feldman D, Verstuyf A. The anti-cancer and anti-inflammatory actions of 1,25(OH)2D3. Best Pract Res Clin Endocrinol Metab. 2011; 25:593–604. 10.1016/j.beem.2011.05.001 [PMC free article] [PubMed] [CrossRef[Google Scholar]
10. Hiatt RA, Krieger N, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N. Prediagnostic serum vitamin D and breast cancer. J Natl Cancer Inst. 1998; 90:461–63. 10.1093/jnci/90.6.461 [PubMed] [CrossRef[Google Scholar]
11. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer. 2010; 46:2196–205. 10.1016/j.ejca.2010.03.037 [PubMed] [CrossRef[Google Scholar]
12. Hong Z, Tian C, Zhang X. Dietary calcium intake, vitamin D levels, and breast cancer risk: a dose-response analysis of observational studies. Breast Cancer Res Treat. 2012; 136:309–12. 10.1007/s10549-012-2172-8 [PubMed] [CrossRef[Google Scholar]
13. Gissel T, Rejnmark L, Mosekilde L, Vestergaard P. Intake of vitamin D and risk of breast cancer—a meta-analysis. J Steroid Biochem Mol Biol. 2008; 111:195–99. 10.1016/j.jsbmb.2008.06.002 [PubMed] [CrossRef[Google Scholar]
14. Estébanez N, Gómez-Acebo I, Palazuelos C, Llorca J, Dierssen-Sotos T. Vitamin D exposure and Risk of Breast Cancer: a meta-analysis. Sci Rep. 2018; 8:9039. 10.1038/s41598-018-27297-1 [PMC free article] [PubMed] [CrossRef[Google Scholar]
15. Bauer SR, Hankinson SE, Bertone-Johnson ER, Ding EL. Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. Medicine (Baltimore). 2013; 92:123–31. 10.1097/MD.0b013e3182943bc2 [PMC free article] [PubMed] [CrossRef[Google Scholar]
16. O’Brien KM, Sandler DP, Taylor JA, Weinberg CR. Serum Vitamin D and Risk of Breast Cancer within Five Years. Environ Health Perspect. 2017; 125:077004. 10.1289/EHP943 [PMC free article] [PubMed] [CrossRef[Google Scholar]
17. Fedirko V, Torres-Mejía G, Ortega-Olvera C, Biessy C, Angeles-Llerenas A, Lazcano-Ponce E, Saldaña-Quiroz VA, Romieu I. Serum 25-hydroxyvitamin D and risk of breast cancer: results of a large population-based case-control study in Mexican women. Cancer Causes Control. 2012; 23:1149–62. 10.1007/s10552-012-9984-z [PubMed] [CrossRef[Google Scholar]
18. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst. 2002; 94:1301–11. 10.1093/jnci/94.17.1301 [PubMed] [CrossRef[Google Scholar]
19. McCullough ML, Rodriguez C, Diver WR, Feigelson HS, Stevens VL, Thun MJ, Calle EE. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2005; 14:2898–904. 10.1158/1055-9965.EPI-05-0611 [PubMed] [CrossRef[Google Scholar]
20. Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women’s Health Study. Cancer Causes Control. 2007; 18:775–82. 10.1007/s10552-007-9020-x [PubMed] [CrossRef[Google Scholar]
21. Lin J, Manson JE, Lee IM, Cook NR, Buring JE, Zhang SM. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 2007; 167:1050–59. 10.1001/archinte.167.10.1050 [PubMed] [CrossRef[Google Scholar]
22. Engel P, Fagherazzi G, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Joint effects of dietary vitamin D and sun exposure on breast cancer risk: results from the French E3N cohort. Cancer Epidemiol Biomarkers Prev. 2011; 20:187–98. 10.1158/1055-9965.EPI-10-1039 [PubMed] [CrossRef[Google Scholar]
23. Edvardsen K, Veierød MB, Brustad M, Braaten T, Engelsen O, Lund E. Vitamin D-effective solar UV radiation, dietary vitamin D and breast cancer risk. Int J Cancer. 2011; 128:1425–33. 10.1002/ijc.25463 [PubMed] [CrossRef[Google Scholar]
24. Abbas S, Linseisen J, Rohrmann S, Chang-Claude J, Peeters PH, Engel P, Brustad M, Lund E, Skeie G, Olsen A, Tjønneland A, Overvad K, Boutron-Ruault MC, et al.. Dietary intake of vitamin D and calcium and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition. Nutr Cancer. 2013; 65:178–87. 10.1080/01635581.2013.752018 [PubMed] [CrossRef[Google Scholar]
25. John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 1999; 8:399–406. [PubMed[Google Scholar]
26. Frazier AL, Li L, Cho E, Willett WC, Colditz GA. Adolescent diet and risk of breast cancer. Cancer Causes Control. 2004; 15:73–82. 10.1023/B:CACO.0000016617.57120.df [PubMed] [CrossRef[Google Scholar]
27. Kuper H, Yang L, Sandin S, Lof M, Adami HO, Weiderpass E. Prospective study of solar exposure, dietary vitamin D intake, and risk of breast cancer among middle-aged women. Cancer Epidemiol Biomarkers Prev. 2009; 18:2558–61. 10.1158/1055-9965.EPI-09-0449 [PubMed] [CrossRef[Google Scholar]
28. Potischman N, Swanson CA, Coates RJ, Gammon MD, Brogan DR, Curtin J, Brinton LA. Intake of food groups and associated micronutrients in relation to risk of early-stage breast cancer. Int J Cancer. 1999; 82:315–21. 10.1002/(SICI)1097-0215(19990730)82:3<315::AID-IJC1>3.0.CO;2-N [PubMed] [CrossRef[Google Scholar]
29. Rossi M, McLaughlin JK, Lagiou P, Bosetti C, Talamini R, Lipworth L, Giacosa A, Montella M, Franceschi S, Negri E, La Vecchia C. Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol. 2009; 20:374–78. 10.1093/annonc/mdn550 [PubMed] [CrossRef[Google Scholar]
30. Anderson LN, Cotterchio M, Vieth R, Knight JA. Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. Am J Clin Nutr. 2010; 91:1699–707. 10.3945/ajcn.2009.28869 [PubMed] [CrossRef[Google Scholar]
31. Kawase T, Matsuo K, Suzuki T, Hirose K, Hosono S, Watanabe M, Inagaki M, Iwata H, Tanaka H, Tajima K. Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan. Cancer Sci. 2010; 101:1234–40. 10.1111/j.1349-7006.2010.01496.x [PubMed] [CrossRef[Google Scholar]
32. Lee MS, Huang YC, Wahlqvist ML, Wu TY, Chou YC, Wu MH, Yu JC, Sun CA. Vitamin D decreases risk of breast cancer in premenopausal women of normal weight in subtropical taiwan. J Epidemiol. 2011; 21:87–94. 10.2188/jea.JE20100088 [PMC free article] [PubMed] [CrossRef[Google Scholar]
33. Rollison DE, Cole AL, Tung KH, Slattery ML, Baumgartner KB, Byers T, Wolff RK, Giuliano AR. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S. Breast Cancer Res Treat. 2012; 132:683–91. 10.1007/s10549-011-1885-4 [PMC free article] [PubMed] [CrossRef[Google Scholar]
34. Abbas S, Linseisen J, Chang-Claude J. Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr Cancer. 2007; 59:54–61. 10.1080/01635580701390223 [PubMed] [CrossRef[Google Scholar]
35. Levi F, Pasche C, Lucchini F, La Vecchia C. Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer. 2001; 91:260–63. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1041>3.0.CO;2-# [PubMed] [CrossRef[Google Scholar]
36. Cheney CP, Thorand B, Huth C, Berger K, Peters A, Seifert-Klauss V, Kiechle M, Strauch K, Quante AS. The Association between Serum 25-Hydroxyvitamin D and Cancer Risk: Results from the Prospective KORA F4 Study. Oncol Res Treat. 2018; 41:117–21. 10.1159/000485512 [PubMed] [CrossRef[Google Scholar]
37. Palmer JR, Gerlovin H, Bethea TN, Bertrand KA, Holick MF, Ruiz-Narvaez EN, Wise LA, Haddad SA, Adams-Campbell LL, Kaufman HW, Rosenberg L, Cozier YC. Predicted 25-hydroxyvitamin D in relation to incidence of breast cancer in a large cohort of African American women. Breast Cancer Res. 2016; 18:86. 10.1186/s13058-016-0745-x [PMC free article] [PubMed] [CrossRef[Google Scholar]
38. Ordóñez-Mena JM, Schöttker B, Fedirko V, Jenab M, Olsen A, Halkjær J, Kampman E, de Groot L, Jansen E, Bueno-de-Mesquita HB, Peeters PH, Siganos G, Wilsgaard T, et al.. Pre-diagnostic vitamin D concentrations and cancer risks in older individuals: an analysis of cohorts participating in the CHANCES consortium. Eur J Epidemiol. 2016; 31:311–23. 10.1007/s10654-015-0040-7 [PubMed] [CrossRef[Google Scholar]
39. Skaaby T, Husemoen LL, Thuesen BH, Pisinger C, Jørgensen T, Roswall N, Larsen SC, Linneberg A. Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev. 2014; 23:1220–29. 10.1158/1055-9965.EPI-14-0007 [PubMed] [CrossRef[Google Scholar]
40. Ordóñez-Mena JM, Schöttker B, Haug U, Müller H, Köhrle J, Schomburg L, Holleczek B, Brenner H. Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2013; 22:905–16. 10.1158/1055-9965.EPI-12-1332 [PubMed] [CrossRef[Google Scholar]
41. McDonnell SL, Baggerly CA, French CB, Baggerly LL, Garland CF, Gorham ED, Hollis BW, Trump DL, Lappe JM. Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations ≥60 vs <20 ng/ml (150 vs 50 nmol/L): pooled analysis of two randomized trials and a prospective cohort. PLoS One. 2018; 13:e0199265. 10.1371/journal.pone.0199265 [PMC free article] [PubMed] [CrossRef[Google Scholar]
42. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14:1991–97. 10.1158/1055-9965.EPI-04-0722 [PubMed] [CrossRef[Google Scholar]
43. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005; 41:1164–69. 10.1016/j.ejca.2005.01.017 [PubMed] [CrossRef[Google Scholar]
44. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer—results of a large case-control study. Carcinogenesis. 2008; 29:93–99. 10.1093/carcin/bgm240 [PubMed] [CrossRef[Google Scholar]
45. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O’Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, et al., and Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008; 100:1581–91. 10.1093/jnci/djn360 [PMC free article] [PubMed] [CrossRef[Google Scholar]
46. Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2008; 17:889–94. 10.1158/1055-9965.EPI-07-2594 [PMC free article] [PubMed] [CrossRef[Google Scholar]
47. Abbas S, Chang-Claude J, Linseisen J. Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer. 2009; 124:250–55. 10.1002/ijc.23904 [PubMed] [CrossRef[Google Scholar]
48. Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL, Neugut AI, Santella RM. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009; 2:598–604. 10.1158/1940-6207.CAPR-08-0138 [PMC free article] [PubMed] [CrossRef[Google Scholar]
49. McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE. Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res. 2009; 11:R64. 10.1186/bcr2356 [PMC free article] [PubMed] [CrossRef[Google Scholar]
50. Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, Mosekilde L. Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2009; 18:2655–60. 10.1158/1055-9965.EPI-09-0531 [PubMed] [CrossRef[Google Scholar]
51. Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J. Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer. 2010; 127:2159–68. 10.1002/ijc.25215 [PubMed] [CrossRef[Google Scholar]
52. Engel P, Fagherazzi G, Boutten A, Dupré T, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev. 2010; 19:2341–50. 10.1158/1055-9965.EPI-10-0264 [PubMed] [CrossRef[Google Scholar]
53. Lope V, Castelló A, Mena-Bravo A, Amiano P, Aragonés N, Fernández-Villa T, Guevara M, Dierssen-Sotos T, Fernandez-Tardón G, Castaño-Vinyals G, Marcos-Gragera R, Moreno V, Salas-Trejo D, et al.. Serum 25-hydroxyvitamin D and breast cancer risk by pathological subtype (MCC-Spain). J Steroid Biochem Mol Biol. 2018; 182:4–13. 10.1016/j.jsbmb.2018.04.005 [PubMed] [CrossRef[Google Scholar]
54. Shirazi L, Almquist M, Borgquist S, Malm J, Manjer J. Serum vitamin D (25OHD3) levels and the risk of different subtypes of breast cancer: A nested case-control study. Breast. 2016; 28:184–90. 10.1016/j.breast.2016.06.002 [PubMed] [CrossRef[Google Scholar]
55. Deschasaux M, Souberbielle JC, Latino-Martel P, Sutton A, Charnaux N, Druesne-Pecollo N, Galan P, Hercberg S, Le Clerc S, Kesse-Guyot E, Ezzedine K, Touvier M. Weight Status and Alcohol Intake Modify the Association between Vitamin D and Breast Cancer Risk. J Nutr. 2016; 146:576–85. 10.3945/jn.115.221481 [PubMed] [CrossRef[Google Scholar]
56. Kühn T, Kaaks R, Becker S, Eomois PP, Clavel-Chapelon F, Kvaskoff M, Dossus L, Tjønneland A, Olsen A, Overvad K, Chang-Claude J, Lukanova A, Buijsse B, et al.. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: a nested case-control study. Int J Cancer. 2013; 133:1689–700. 10.1002/ijc.28172 [PubMed] [CrossRef[Google Scholar]
57. Pazdiora P, Svobodova S, Fuchsova R, Kucera R, Prazakova M, Vrzalova J, Narsanska A, Strakova M, Treskova I, Pecen L, Treska V, Holubec L Jr, Pesek M, et al.. Vitamin D in colorectal, breast, prostate and lung cancer: a pilot study. Anticancer Res. 2011; 31:3619–21. [PubMed[Google Scholar]
58. Eliassen AH, Warner ET, Rosner B, Collins LC, Beck AH, Quintana LM, Tamimi RM, Hankinson SE. Plasma 25-Hydroxyvitamin D and Risk of Breast Cancer in Women Followed over 20 Years. Cancer Res. 2016; 76:5423–30. 10.1158/0008-5472.CAN-16-0353 [PMC free article] [PubMed] [CrossRef[Google Scholar]
59. Mohr SB, Gorham ED, Alcaraz JE, Kane CI, Macera CA, Parsons JK, Wingard DL, Horst R, Garland CF. Serum 25-hydroxyvitamin D and breast cancer in the military: a case-control study utilizing pre-diagnostic serum. Cancer Causes Control. 2013; 24:495–504. 10.1007/s10552-012-0140-6 [PubMed] [CrossRef[Google Scholar]
60. Neuhouser ML, Manson JE, Millen A, Pettinger M, Margolis K, Jacobs ET, Shikany JM, Vitolins M, Adams-Campbell L, Liu S, LeBlanc E, Johnson KC, Wactawski-Wende J. The influence of health and lifestyle characteristics on the relation of serum 25-hydroxyvitamin D with risk of colorectal and breast cancer in postmenopausal women. Am J Epidemiol. 2012; 175:673–84. 10.1093/aje/kwr350 [PMC free article] [PubMed] [CrossRef[Google Scholar]
61. Peppone LJ, Rickles AS, Janelsins MC, Insalaco MR, Skinner KA. The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol. 2012; 19:2590–99. 10.1245/s10434-012-2297-3 [PMC free article] [PubMed] [CrossRef[Google Scholar]
62. Yao S, Sucheston LE, Millen AE, Johnson CS, Trump DL, Nesline MK, Davis W, Hong CC, McCann SE, Hwang H, Kulkarni S, Edge SB, O’Connor TL, Ambrosone CB. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS One. 2011; 6:e17251. 10.1371/journal.pone.0017251 [PMC free article] [PubMed] [CrossRef[Google Scholar]
63. Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res. 2011; 13:R50. 10.1186/bcr2880 [PMC free article] [PubMed] [CrossRef[Google Scholar]
64. Budhathoki S, Hidaka A, Yamaji T, Sawada N, Tanaka-Mizuno S, Kuchiba A, Charvat H, Goto A, Kojima S, Sudo N, Shimazu T, Sasazuki S, Inoue M, et al., and Japan Public Health Center-based Prospective Study Group. Plasma 25-hydroxyvitamin D concentration and subsequent risk of total and site specific cancers in Japanese population: large case-cohort study within Japan Public Health Center-based Prospective Study cohort. BMJ. 2018; 360:k671. 10.1136/bmj.k671 [PMC free article] [PubMed] [CrossRef[Google Scholar]
65. Colagar AH, Firouzjah HM, Halalkhor S, Vitamin D. Vitamin D Receptor Poly(A) Microsatellite Polymorphism and 25-Hydroxyvitamin D Serum Levels: Association with Susceptibility to Breast Cancer. J Breast Cancer. 2015; 18:119–25. 10.4048/jbc.2015.18.2.119 [PMC free article] [PubMed] [CrossRef[Google Scholar]
66. Yousef FM, Jacobs ET, Kang PT, Hakim IA, Going S, Yousef JM, Al-Raddadi RM, Kumosani TA, Thomson CA. Vitamin D status and breast cancer in Saudi Arabian women: case-control study. Am J Clin Nutr. 2013; 98:105–10. 10.3945/ajcn.112.054445 [PMC free article] [PubMed] [CrossRef[Google Scholar]
67. Chen P, Li M, Gu X, Liu Y, Li X, Li C, Wang Y, Xie D, Wang F, Yu C, Li J, Chen X, Chu R, et al.. Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studies. PLoS One. 2013; 8:e49312. 10.1371/journal.pone.0049312 [PMC free article] [PubMed] [CrossRef[Google Scholar]
68. Atoum MF, Al-Khatib YM. Association between Serum 25-hydroxy Vitamin D Concentration and TaqI Vitamin D Receptor Gene Polymorphism among Jordanian Females with Breast Cancer. Chin Med J (Engl). 2017; 130:1074–78. 10.4103/0366-6999.204933 [PMC free article] [PubMed] [CrossRef[Google Scholar]
69. Jamshidinaeini Y, Akbari ME, Abdollahi M, Ajami M, Davoodi SH. Vitamin D Status and Risk of Breast Cancer in Iranian Women: A Case-Control Study. J Am Coll Nutr. 2016; 35:639–46. 10.1080/07315724.2015.1127786 [PubMed] [CrossRef[Google Scholar]
70. Alipour S, Hadji M, Hosseini L, Omranipour R, Saberi A, Seifollahi A, Bayani L, Shirzad N. Levels of serum 25-hydroxy-vitamin d in benign and malignant breast masses. Asian Pac J Cancer Prev. 2014; 15:129–32. 10.7314/APJCP.2014.15.1.129 [PubMed] [CrossRef[Google Scholar]
71. Bidgoli SA, Azarshab H. Role of vitamin D deficiency and lack of sun exposure in the incidence of premenopausal breast cancer: a case control study in Sabzevar, Iran. Asian Pac J Cancer Prev. 2014; 15:3391–96. 10.7314/APJCP.2014.15.8.3391 [PubMed] [CrossRef[Google Scholar]
72. Imtiaz S, Siddiqui N, Raza SA, Loya A, Muhammad A. Vitamin D deficiency in newly diagnosed breast cancer patients. Indian J Endocrinol Metab. 2012; 16:409–13. 10.4103/2230-8210.95684 [PMC free article] [PubMed] [CrossRef[Google Scholar]
73. Sofi NY, Jain M, Kapil U, Seenu V, Kamal VK, Pandey RM. Nutritional risk factors and status of serum 25(OH)D levels in patients with breast cancer: A case control study in India. J Steroid Biochem Mol Biol. 2018; 175:55–59. 10.1016/j.jsbmb.2016.09.020 [PubMed] [CrossRef[Google Scholar]
74. Sofi NY, Jain M, Kapil U, Seenu V, R L, Yadav CP, Pandey RM, Sareen N. Reproductive factors, nutritional status and serum 25(OH)D levels in women with breast cancer: A case control study. J Steroid Biochem Mol Biol. 2018; 175:200–04. 10.1016/j.jsbmb.2017.11.003 [PubMed] [CrossRef[Google Scholar]
75. Park S, Lee DH, Jeon JY, Ryu J, Kim S, Kim JY, Park HS, Kim SI, Park BW. Serum 25-hydroxyvitamin D deficiency and increased risk of breast cancer among Korean women: a case-control study. Breast Cancer Res Treat. 2015; 152:147–54. 10.1007/s10549-015-3433-0 [PubMed] [CrossRef[Google Scholar]
76. Anderson LN, Cotterchio M, Kirsh VA, Knight JA. Ultraviolet sunlight exposure during adolescence and adulthood and breast cancer risk: a population-based case-control study among Ontario women. Am J Epidemiol. 2011; 174:293–304. 10.1093/aje/kwr091 [PubMed] [CrossRef[Google Scholar]
77. Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat. 2012; 133:1077–88. 10.1007/s10549-012-2012-x [PMC free article] [PubMed] [CrossRef[Google Scholar]
78. Bilinski K, Boyages J. Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: an observational case-control study. Breast Cancer Res Treat. 2013; 137:599–607. 10.1007/s10549-012-2381-1 [PubMed] [CrossRef[Google Scholar]
79. Oliveira Sediyama CM, Dias MM, Pessoa MC, Queiroz AR, Suhett LG, Freitas RN, De Paula SO, Peluzio MD. Lifestyle and vitamin D dosage in women with breast cancer. Nutr Hosp. 2016; 33:584. 10.20960/nh.584 [PubMed] [CrossRef[Google Scholar]
80. Scarmo S, Afanasyeva Y, Lenner P, Koenig KL, Horst RL, Clendenen TV, Arslan AA, Chen Y, Hallmans G, Lundin E, Rinaldi S, Toniolo P, Shore RE, Zeleniuch-Jacquotte A. Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: a nested case-control study. Breast Cancer Res. 2013; 15:R15. 10.1186/bcr3390 [PMC free article] [PubMed] [CrossRef[Google Scholar]
81. Wu Y, Sarkissyan M, Clayton S, Chlebowski R, Vadgama JV. Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. Cancers (Basel). 2017; 9:E144. 10.3390/cancers9100144 [PMC free article] [PubMed] [CrossRef[Google Scholar]
82. Kim Y, Franke AA, Shvetsov YB, Wilkens LR, Cooney RV, Lurie G, Maskarinec G, Hernandez BY, Le Marchand L, Henderson BE, Kolonel LN, Goodman MT. Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: a nested case-control study in the multiethnic cohort study. BMC Cancer. 2014; 14:29. 10.1186/1471-2407-14-29 [PMC free article] [PubMed] [CrossRef[Google Scholar]
83. Veldhuis S, Wolbers F, Brouckaert O, Vermes I, Franke HR. Cancer prevalence in osteoporotic women with low serum vitamin D levels. Menopause. 2011; 18:319–22. 10.1097/gme.0b013e3181f81ad5 [PubMed] [CrossRef[Google Scholar]
84. Grant WB. A Review of the Evidence Supporting the Vitamin D-Cancer Prevention Hypothesis in 2017. Anticancer Res. 2018; 38:1121–36. 10.21873/anticanres.12331 [PubMed] [CrossRef[Google Scholar]
85. Gilbert R, Bonilla C, Metcalfe C, Lewis S, Evans DM, Fraser WD, Kemp JP, Donovan JL, Hamdy FC, Neal DE, Lane JA, Smith GD, Lathrop M, Martin RM. Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. Cancer Causes Control. 2015; 26:205–18. 10.1007/s10552-014-0500-5 [PMC free article] [PubMed] [CrossRef[Google Scholar]
86. Chandler PD, Buring JE, Manson JE, Giovannucci EL, Moorthy MV, Zhang S, Lee IM, Lin JH. Circulating Vitamin D Levels and Risk of Colorectal Cancer in Women. Cancer Prev Res (Phila). 2015; 8:675–82. 10.1158/1940-6207.CAPR-14-0470 [PMC free article] [PubMed] [CrossRef[Google Scholar]
87. McCullough ML, Zoltick ES, Weinstein SJ, Fedirko V, Wang M, Cook NR, Eliassen AH, Zeleniuch-Jacquotte A, Agnoli C, Albanes D, Barnett MJ, Buring JE, Campbell PT, et al.. Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts. J Natl Cancer Inst. 2019; 111:158–69. 10.1093/jnci/djy087 [PMC free article] [PubMed] [CrossRef[Google Scholar]
88. Gao J, Wei W, Wang G, Zhou H, Fu Y, Liu N. Circulating vitamin D concentration and risk of prostate cancer: a dose-response meta-analysis of prospective studies. Ther Clin Risk Manag. 2018; 14:95–104. 10.2147/TCRM.S149325 [PMC free article] [PubMed] [CrossRef[Google Scholar]
89. Cattaruzza MS, Pisani D, Fidanza L, Gandini S, Marmo G, Narcisi A, Bartolazzi A, Carlesimo M. 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies. Eur J Cancer Prev. 2019; 28:203–11. 10.1097/CEJ.0000000000000437 [PubMed] [CrossRef[Google Scholar]
90. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology. 1981; 108:1083–86. 10.1210/endo-108-3-1083 [PubMed] [CrossRef[Google Scholar]
91. Huhtakangas JA, Veijola J, Turunen S, Karjalainen A, Valkealahti M, Nousiainen T, Yli-Luukko S, Vuolteenaho O, Lehenkari P. 1,25(OH)2D3 and calcipotriol, its hypocalcemic analog, exert a long-lasting anti-inflammatory and anti-proliferative effect in synoviocytes cultured from patients with rheumatoid arthritis and osteoarthritis. J Steroid Biochem Mol Biol. 2017; 173:13–22. 10.1016/j.jsbmb.2017.01.017 [PubMed] [CrossRef[Google Scholar]
92. Chen L, Yang R, Qiao W, Yuan X, Wang S, Goltzman D, Miao D. 1,25-Dihydroxy vitamin D prevents tumorigenesis by inhibiting oxidative stress and inducing tumor cellular senescence in mice. Int J Cancer. 2018; 143:368–82. 10.1002/ijc.31317 [PubMed] [CrossRef[Google Scholar]
93. Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014; 110:2772–84. 10.1038/bjc.2014.175 [PMC free article] [PubMed] [CrossRef[Google Scholar]
94. Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, et al.. Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prev Res (Phila). 2019; 12:481–90. 10.1158/1940-6207.CAPR-18-0444 [PMC free article] [PubMed] [CrossRef[Google Scholar]
95. Li J, Li B, Jiang Q, Zhang Y, Liu A, Wang H, Zhang J, Qin Q, Hong Z, Li BA. Do genetic polymorphisms of the vitamin D receptor contribute to breast/ovarian cancer? A systematic review and network meta-analysis. Gene. 2018; 677:211–27. 10.1016/j.gene.2018.07.070 [PubMed] [CrossRef[Google Scholar]
96. Shi J, Grundy A, Richardson H, Burstyn I, Schuetz JM, Lohrisch CA, SenGupta SK, Lai AS, Brooks-Wilson A, Spinelli JJ, Aronson KJ. Genetic variation in vitamin D-related genes and risk of breast cancer among women of European and East Asian descent. Tumour Biol. 2016; 37:6379–87. 10.1007/s13277-015-4417-8 [PubMed] [CrossRef[Google Scholar]
97. Shahbazi S, Alavi S, Majidzadeh-A K, Ghaffarpour M, Soleimani A, Mahdian R. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013; 30:393. 10.1007/s12032-012-0393-7 [PubMed] [CrossRef[Google Scholar]
98. Wang J, Eliassen AH, Spiegelman D, Willett WC, Hankinson SE. Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses’ Health Study II. Cancer Causes Control. 2014; 25:819–27. 10.1007/s10552-014-0383-5 [PMC free article] [PubMed] [CrossRef[Google Scholar]
99. Vojdeman FJ, Madsen CM, Frederiksen K, Durup D, Olsen A, Hansen L, Heegaard AM, Lind B, Tjønneland A, Jørgensen HL, Schwarz P. Vitamin D levels and cancer incidence in 217,244 individuals from primary health care in Denmark. Int J Cancer. 2019; 145:338–46. 10.1002/ijc.32105 [PubMed] [CrossRef[Google Scholar]
100. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25:603–05. 10.1007/s10654-010-9491-z [PubMed] [CrossRef[Google Scholar]
101. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539–58. 10.1002/sim.1186 [PubMed] [CrossRef[Google Scholar]
102. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015; 45:139–45. 10.1016/j.cct.2015.09.002 [PMC free article] [PubMed] [CrossRef[Google Scholar]
103. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992; 135:1301–09. 10.1093/oxfordjournals.aje.a116237 [PubMed] [CrossRef[Google Scholar]
104. Liu Q, Cook NR, Bergström A, Hsieh CC. A two-stage hierarchical regression model for meta-analysis of epidemiologic nonlinear dose–response data. Comput Stat Data Anal. 2009; 53:4157–67. 10.1016/j.csda.2009.05.001 [CrossRef[Google Scholar]
105. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2012; 175:66–73. 10.1093/aje/kwr265 [PMC free article] [PubMed] [CrossRef[Google Scholar] 106.www.ncbi.nlm.nih.gov/pubmed/24705652